Aktis Oncology, Inc. Common stock (AKTS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aktis Oncology, Inc. Common stock (AKTS) has a cash flow conversion efficiency ratio of 0.146x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.80 Million) by net assets ($-87.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Aktis Oncology, Inc. Common stock worth for the company's overall valuation and market capitalisation.
Aktis Oncology, Inc. Common stock - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Aktis Oncology, Inc. Common stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aktis Oncology, Inc. Common stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aktis Oncology, Inc. Common stock ranked by their cash flow conversion efficiency. See debt repayment capacity of Aktis Oncology, Inc. Common stock to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The India Cements Limited
NSE:INDIACEM
|
-0.019x |
|
Manchester United Ltd
NYSE:MANU
|
0.005x |
|
EcoRodovias Infraestrutura e Logística S.A
SA:ECOR3
|
0.322x |
|
Instalco Intressenter AB
ST:INSTAL
|
0.028x |
|
Rastar Environmental Protection Materials Co.Ltd.
SHE:300834
|
0.021x |
|
VIEL & Cie société anonyme
PA:VIL
|
0.111x |
|
Red Star Macalline Group Corp Ltd Class A
SHG:601828
|
0.009x |
|
Stx Heavy Indu
KO:071970
|
0.064x |
Annual Cash Flow Conversion Efficiency for Aktis Oncology, Inc. Common stock (2014–2024)
The table below shows the annual cash flow conversion efficiency of Aktis Oncology, Inc. Common stock from 2014 to 2024. View AKTS live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-87.80 Million | $14.76 Million | -0.168x | -123.79% |
| 2024-06-30 | $-57.09 Million | $-40.35 Million | 0.707x | +9.06% |
| 2023-12-31 | $-46.31 Million | $-30.00 Million | 0.648x | +224.67% |
| 2023-06-30 | $86.24 Million | $-44.82 Million | -0.520x | -155.14% |
| 2022-12-31 | $-19.23 Million | $-18.12 Million | 0.943x | +315.70% |
| 2022-06-30 | $103.43 Million | $-45.20 Million | -0.437x | 0.00% |
| 2021-12-31 | $103.43 Million | $-45.20 Million | -0.437x | -74.72% |
| 2021-06-30 | $117.41 Million | $-29.36 Million | -0.250x | +51.29% |
| 2020-12-31 | $41.49 Million | $-21.30 Million | -0.513x | 0.00% |
| 2020-06-30 | $41.49 Million | $-21.30 Million | -0.513x | +24.57% |
| 2019-12-31 | $25.95 Million | $-17.67 Million | -0.681x | 0.00% |
| 2019-06-30 | $25.95 Million | $-17.67 Million | -0.681x | +33.61% |
| 2018-12-31 | $13.85 Million | $-14.20 Million | -1.025x | 0.00% |
| 2018-06-30 | $13.85 Million | $-14.20 Million | -1.025x | -177.37% |
| 2017-12-31 | $15.01 Million | $-5.55 Million | -0.370x | 0.00% |
| 2017-06-30 | $15.01 Million | $-5.55 Million | -0.370x | +10.09% |
| 2016-06-30 | $2.68 Million | $-1.10 Million | -0.411x | 0.00% |
| 2015-12-31 | $2.68 Million | $-1.10 Million | -0.411x | -75.57% |
| 2015-06-30 | $4.19 Million | $-980.04K | -0.234x | 0.00% |
| 2014-12-31 | $4.19 Million | $-980.04K | -0.234x | +92.00% |
| 2014-06-30 | $9.21K | $-26.98K | -2.928x | -- |
About Aktis Oncology, Inc. Common stock
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatmen… Read more